Immuno-oncology company Agenus Inc (NASDAQ:AGEN) reported on Thursday the receipt of the Bill & Melinda Gates Foundation's USD1m grant to jointly develop an alternative, plant cell culture-based manufacturing process to ensure the continuous future supply of its QS-21 Stimulon adjuvant to power vaccines.
Agenus' QS-21 Stimulon is a proprietary adjuvant, currently incorporated as part of Glaxo Smith Kline's (GSK's) highly efficacious Shingrix vaccine. The QS-21 Stimulon is also used in GSK's Mosquirix vaccine and numerous other clinical-stage vaccines, including Agenus' own cancer vaccines.
QS-21 is currently extracted from Chilean soap bark trees, exclusively sourced from a localized area in Chile. Agenus now plans to develop a cell-culture based, environment friendly manufacturing technique as an alternative future supply.
The company added that the alternative manufacturing process for QS-21 will be developed in an exclusive partnership with Phyton Biotech2. Leveraging its Plant Cell Fermentation (PCF) technology, Phyton Biotech will attempt to demonstrate that PCF is a feasible model for the consistent, large-scale and low-cost commercial production of high-quality QS-21 directly from plant cell cultures.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma